Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer

Journal of Ovarian Research

Research

Xiayu Jin¹  Yisheng Wang¹  Ming Du¹  Yingying Lu¹  Yuefei Wang¹  Xiaoyan Zhang²  Congjian Xu² 

[1] Obstetrics and Gynecology Hospital, Fudan University, 200011, Shanghai, China;Obstetrics and Gynecology Hospital, Fudan University, 200011, Shanghai, China;Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, 200011, Shanghai, China;Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai 200032, China;

关键词: Ovarian cancer;    CA125;    Tn antigen;    Cytoreductive surgery;    Peritoneal dissemination;    Residual disease;   

DOI  :  10.1186/s13048-022-01066-1

 received in 2022-09-13, accepted in 2022-11-22,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundPeritoneal dissemination is the predominant feature of malignant progression in ovarian cancer and is a major cause of poor surgical outcomes and clinical prognoses. Abnormal glycosylation of carbohydrate antigen 125 (CA125) may be involved in peritoneal implantation and metastasis. Here, we evaluated the clinical relevance of CA125-Tn glycoform in the assessment of high-grade serous ovarian cancer (HGSOC).MethodsA total of 72 patients diagnosed with HGSOC were included. Pre-treatment serum CA125-Tn levels were measured using an antibody-lectin enzyme-linked immunosorbent assay. The association of CA125-Tn with clinical factors was analyzed in all cases, whereas its association with peritoneal dissemination, residual disease, and progression-free survival was analyzed in stage III–IV cases.ResultsPre-treatment serum CA125-Tn levels were significantly higher in advanced-stage HGSOC patients than in early-stage patients (P = 0.029). In advanced-stage patients, the pre-treatment CA125-Tn level increased with an increase in Fagotti’s score (P = 0.004) and with the extension of peritoneal dissemination (P = 0.011). The pre-treatment CA125-Tn level increased with the volume of residual disease (P = 0.005). The association between CA125-Tn level and suboptimal surgery remained significant even after adjustment for treatment type and stage. Pre-treatment CA125-Tn levels were also related to disease recurrence.ConclusionSerum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq22.gif

Fig. 2